Arno Therapeutics Inc (ARNI) financial statements (2022 and earlier)

Company profile

Business Address 200 ROUTE 31 NORTH
FLEMINGTON, NJ 08822
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments677,94826,77410,943
Cash and cash equivalents677,94826,77410,943
Prepaid expense and other current assets204
Other undisclosed current assets26125886 
Total current assets:3288,20626,86011,147
Noncurrent Assets
Property, plant and equipment23311225
Deposits noncurrent assets10101010
Deferred costs   1,710
Total noncurrent assets:3441221,745
TOTAL ASSETS:3618,24826,88312,892
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1,0107422,9421,553
Accounts payable1,0107422,9421,553
Debt43  
Due to related parties  2628
Deferred revenue and credits21813
Other undisclosed current liabilities3,2151,4109251,652
Total current liabilities:4,2312,1573,9013,246
Noncurrent Liabilities
Long-term debt and lease obligation48  
Capital lease obligations48  
Liabilities, other than long-term debt4,7516,67235,86521,420
Derivative instruments and hedges, liabilities4,7516,67235,86521,420
Other undisclosed noncurrent liabilities   491
Total noncurrent liabilities:4,7556,67935,86521,911
Total liabilities:8,9858,83739,76625,158
Stockholders' equity
Stockholders' equity attributable to parent, including:(8,624)(589)(12,883)(12,266)
Common stock5554
Additional paid in capital84,66581,19376,66937,631
Accumulated deficit(93,295)   
Warrants and rights outstanding   12,431
Other undisclosed stockholders' equity attributable to parent (81,787)(89,558)(62,331)
Total stockholders' equity:(8,624)(589)(12,883)(12,266)
TOTAL LIABILITIES AND EQUITY:3618,24826,88312,892

Income statement (P&L) ($ in thousands)

12/31/2015
12/31/2014
12/31/2013
12/31/2012
Operating expenses(13,412)(21,493)(16,941)(10,836)
Operating loss:(13,412)(21,493)(16,941)(10,836)
Nonoperating income (expense)1,90429,264(22,716)(3,552)
Debt instrument, convertible, beneficial conversion feature 7,549  
Other nonoperating income (expense)1,92529,222(4,165)2,801
Interest and debt expense(28)(0)(2,174)(6,361)
Net income (loss):(11,536)7,771(41,831)(20,749)
Other undisclosed net income attributable to parent2802,1746,361
Net income (loss) available to common stockholders, basic:(11,508)7,771(39,657)(14,388)
Dilutive securities, effect on basic earnings per share  39,775 
Net income (loss) available to common stockholders, diluted:(11,508)7,771118(14,388)

Comprehensive Income ($ in thousands)

12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net income (loss):(11,536)7,771(41,831)(20,749)
Comprehensive income (loss), net of tax, attributable to parent:(11,536)7,771(41,831)(20,749)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: